Gavi, the Vaccine Alliance, will increase funding for fragile and humanitarian settings by 15 percent, despite financial constraints, as part of reforms for its Gavi 6.0 (2026–2030) strategy. This new plan prioritizes vulnerable children in low-income countries and aims to give countries greater control over their immunization programs.

• Nearly 90 percent of vaccine procurement funds will be allocated directly to countries, replacing rolling applications with clear five-year vaccine budgets.
• Gavi (The Vaccine Alliance) is a global public–private partnership founded in 2000 that supports low- and middle-income countries' access to vaccines.
• The Gavi Board provisionally approved adding nine-valent HPV vaccines for cervical cancer prevention and endorsed tuberculosis, mpox, and respiratory syncytial virus (RSV) vaccines as priority antigens under the African Vaccine Manufacturing Accelerator (AVMA).